Literature DB >> 29804271

A case of drug-induced Graves' Orbitopathy after combination therapy with Tremelimumab and Durvalumab.

E Sabini1,2, A Sframeli3, M Marinò4.   

Abstract

Entities:  

Keywords:  Durvalumab; Graves’ orbitopathy; Tremelimumab

Mesh：

Substances：

Year:  2018        PMID： 29804271     DOI： 10.1007/s40618-018-0906-0

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  4 in total

1.  Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study.

Authors:  M Leo; F Maggi; G R Dottore; G Casini; P Mazzetti; M Pistello; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2016-12-16       Impact factor: 4.256

2.  Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.

Authors:  Michael R Robinson; Chi-Chao Chan; James C Yang; Benjamin I Rubin; Gerald J Gracia; H Nida Sen; Karl G Csaky; Steven A Rosenberg
Journal:  J Immunother       Date:  2004 Nov-Dec       Impact factor: 4.456

Review 3.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

Review 4.  Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.

Authors:  H X Li; N Xiang; W K Hu; X L Jiao
Journal:  J Endocrinol Invest       Date:  2016-05-24       Impact factor: 4.256
  4 in total
  6 in total

Review 1.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

2.  Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study.

Authors:  Norio Okada; Shintaro Iwama; Takayuki Okuji; Tomoko Kobayashi; Yoshinori Yasuda; Eri Wada; Takeshi Onoue; Motomitsu Goto; Mariko Sugiyama; Taku Tsunekawa; Hiroshi Takagi; Daisuke Hagiwara; Yoshihiro Ito; Hidetaka Suga; Ryoichi Banno; Tetsunari Hase; Masahiro Morise; Mitsuro Kanda; Kenji Yokota; Naozumi Hashimoto; Masahiko Ando; Yasushi Fujimoto; Masato Nagino; Yasuhiro Kodera; Mitsuhiro Fujishiro; Hideharu Hibi; Michihiko Sone; Hitoshi Kiyoi; Momokazu Gotoh; Yuichi Ando; Masashi Akiyama; Yoshinori Hasegawa; Hiroshi Arima
Journal:  Br J Cancer       Date:  2020-02-03       Impact factor: 7.640

Review 3.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03

4.  Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.

Authors:  Xin Pan; Minxiao Yi; Chaofan Liu; Yu Jin; Bo Liu; Guangyuan Hu; Xianglin Yuan
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

Review 5.  Various clinical presentations of uveitis associated with durvalumab treatment.

Authors:  Nika Vrabic; Ana Fakin; Polona Jaki Mekjavic; Urska Janzic; Martina Vrankar; Natasa Vidovic Valentincic
Journal:  Radiol Oncol       Date:  2022-04-12       Impact factor: 4.214

Review 6.  Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.

Authors:  Lin Zhou; Xin Wei
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.